Journal
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Volume 12, Issue 4, Pages 223-229Publisher
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clml.2012.04.002
Keywords
Chronic myelogenous leukemia; Dasatinib; Imatinib; Medication possession ratio; Nilotinib
Categories
Funding
- Bristol-Myers Squibb
- Novartis
- Pfizer
- Ariad
Ask authors/readers for more resources
Treatment for chronic myeloid leukemia (CML) has improved substantially in the past 20 years, especially since the introduction of oral BCR-ABL inhibitors a decade ago. However, for patients to reap the benefits of BCR-ABL inhibitors, they must likely receive therapy for the remainder of their lives. In this situation, adherence to medication becomes a concern. Adherence to therapy for chronic health conditions, including CML, has been demonstrated to be poor. Studies have shown nonadherence in CML to be common in one-third or more of patients, and 100% adherence is rare. Furthermore, evidence suggests that reduced adherence to BCR-ABL inhibitors is associated with reduced efficacy and increased healthcare costs. Factors that can cause nonadherence, including dose, toxicity, time from diagnosis to prescription, and the number of concomitant medications, should be addressed and monitored by the physician. To maximize adherence, CML treatment should be individualized to the patient and simplified as appropriate. Clinical Lymphoma, Myeloma & Leukemia, Vol. 12, No. 4, 223-9 (C) 2012 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available